DESMODA
Launchdesmopressin acetate oral solution
NDAORALSOLUTION
Approved
Feb 2026
Lifecycle
Launch
Competitive Pressure
0/100
Data completeness
4/8 — Partial
DESMODA (desmopressin acetate oral solution) is acetate's primary pharmacodynamic action involves its binding to vasopressin 2 (v2) receptors. Approved for nephrogenic diabetes insipidus, central diabetes insipidus. First approved in 2026.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DESMODA is an oral solution formulation of desmopressin acetate, a synthetic vasopressin analog that binds to V2 receptors in the kidney's collecting ducts to enhance water reabsorption. It treats both central and nephrogenic diabetes insipidus by restoring the body's ability to concentrate urine and maintain water balance. This represents a new oral dosage form option for patients previously limited to intranasal or injectable routes.
Launch17.8 years to LOE
Early-stage launch with zero identified competitors creates greenfield opportunity; commercial team will focus on market education and physician adoption in a niche indication.
Mechanism of Action
acetate's primary pharmacodynamic action involves its binding to vasopressin 2 (V2) receptors. V2 receptors are primarily located in the distal convoluted tubule and collecting ducts of the nephron in the kidneys. These receptors play a crucial role in regulating water reabsorption and urine…
Indications (2)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.